Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis

BACKGROUND: The current standard of care for the management of patients with newly diagnosed glioblastoma (GBM) includes maximal safe resection followed by radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ). While it is well established that TMZ has better efficacy in patients with MG...

Descripción completa

Detalles Bibliográficos
Autores principales: Alnahhas, Iyad, Alsawas, Mouaz, Rayi, Appaji, Palmer, Joshua D, Raval, Raju, Ong, Shirley, Giglio, Pierre, Murad, Mohammad Hassan, Puduvalli, Vinay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596890/
https://www.ncbi.nlm.nih.gov/pubmed/33150334
http://dx.doi.org/10.1093/noajnl/vdaa082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596890/
https://www.ncbi.nlm.nih.gov/pubmed/33150334
http://dx.doi.org/10.1093/noajnl/vdaa082

Ejemplares similares